<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598610</url>
  </required_header>
  <id_info>
    <org_study_id>CTD-2012-002-01</org_study_id>
    <nct_id>NCT01598610</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of an Investigational Blood Glucose Monitoring System</brief_title>
  <official_title>Performance of the CONTOUR® PLUS Blood Glucose Monitoring System With CONTOUR® PLUS Strip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascensia Diabetes Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that untrained subjects who have diabetes can
      operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose
      results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Venous Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. Venous plasma BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 20% (&gt;=75mg/dL YSI venous plasma) of the reference method results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma) of the reference method results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method When Tested by Study Staff</measure>
    <time_frame>1 hour</time_frame>
    <description>Study staff test subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements</measure>
    <time_frame>1 hour</time_frame>
    <description>Subjects respond to statements read by study staff to provide feedback on the labeling materials and system ease of use. Subjects may respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONTOUR® PLUS Investigational BG Monitoring System</intervention_name>
    <description>Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.</description>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years of age and older

          -  Type 1 or type 2 diabetes

          -  Able to speak, read, and understand English

          -  Willing to complete all study procedures

        Exclusion Criteria:

          -  Pregnancy

          -  Hemophilia or any other bleeding disorder

          -  Previously participated in a study using the CONTOUR PLUS system

          -  Working for a medical laboratory, hospital or other clinical setting that involves
             training on and clinical use of blood glucose monitors.

          -  Working for a competitive medical device company, or having an immediate family member
             or someone who is not a family member but is living within the household of someone
             who works for such a company.

          -  A condition, which in the opinion of the investigator, would put the person or study
             conduct at risk (reason for exclusion will be clearly documented by investigator or
             designee).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip D Toth, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Institute For Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Caswell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consumer Product Testing Co.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Institute For Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consumer Product Testing Co.</name>
      <address>
        <city>Fairfield</city>
        <state>New Jersey</state>
        <zip>07004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>May 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="26" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
        <time_frame>1 hour</time_frame>
        <population>216 (220-4) blood test results were analyzed. Blood data for 2 subjects were not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick results were obtained for 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
          <population>216 (220-4) blood test results were analyzed. Blood data for 2 subjects were not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick results were obtained for 2 subjects.</population>
          <units>percentage of BG Test Results</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
        <time_frame>1 hour</time_frame>
        <population>213 (220-7) blood test results were analyzed. Four(4) subjects had low blood sugar and AST results were not evaluable per protocol. One(1) subject with low blood sugar (AE) did not attempt AST testing per protocol. No AST palm results were obtained for 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
          <population>213 (220-7) blood test results were analyzed. Four(4) subjects had low blood sugar and AST results were not evaluable per protocol. One(1) subject with low blood sugar (AE) did not attempt AST testing per protocol. No AST palm results were obtained for 2 subjects.</population>
          <units>percentage of BG Test Results</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Venous Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. Venous plasma BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 20% (&gt;=75mg/dL YSI venous plasma) of the reference method results.</description>
        <time_frame>1 hour</time_frame>
        <population>213 (220-7) blood test results were analyzed. Venipuncture was unsuccessful for 6 subjects. Blood data for 1 subject was not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Venous Blood Glucose Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
          <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. Venous plasma BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 20% (&gt;=75mg/dL YSI venous plasma) of the reference method results.</description>
          <population>213 (220-7) blood test results were analyzed. Venipuncture was unsuccessful for 6 subjects. Blood data for 1 subject was not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method.</population>
          <units>percentage of BG Test Results</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma) of the reference method results.</description>
        <time_frame>1 hour</time_frame>
        <population>108 (110-2) blood test results from one test strip lot were analyzed. Blood data for 1 subject was not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick result was obtained for 1 subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma) of the reference method results.</description>
          <population>108 (110-2) blood test results from one test strip lot were analyzed. Blood data for 1 subject was not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick result was obtained for 1 subject.</population>
          <units>percentage of BG Test Results</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% within +/-15mg/dL(&lt;100mg/dL) or 15% (&gt;=100mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>w/in +/-12.5mg/dL(&lt;100mg/dL) or 12.5% (&gt;=100mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>w/in +/-10mg/dL(&lt;100mg/dL) or +/- 10% (&gt;=100mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>w/in +/-5mg/dL(&lt;100mg/dL) or +/- 5% (&gt;=100mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method When Tested by Study Staff</title>
        <description>Study staff test subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
        <time_frame>1 hour</time_frame>
        <population>217 (220-3) blood test results were analyzed. Blood data for 2 subjects were not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick results were obtained for 1 subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method When Tested by Study Staff</title>
          <description>Study staff test subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. BG results are used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma) of the reference method results.</description>
          <population>217 (220-3) blood test results were analyzed. Blood data for 2 subjects were not evaluable because time, defined in protocol, was exceeded between meter test and blood sample preparation for reference method. No fingerstick results were obtained for 1 subject.</population>
          <units>percentage of BG Test Results</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements</title>
        <description>Subjects respond to statements read by study staff to provide feedback on the labeling materials and system ease of use. Subjects may respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
        <time_frame>1 hour</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements</title>
          <description>Subjects respond to statements read by study staff to provide feedback on the labeling materials and system ease of use. Subjects may respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I found it easy to do a blood test with this meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meter display(test result) is easy to see and read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>It was easy to understand my test results.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like the overall meter design.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I find the meter easy to handle.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy to handle the individual test strips.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instructions (User Guide) easy to understand.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instructions clearly explain how to run a test.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instructions clearly explain meter error messages.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carmine Greene</name_or_title>
      <organization>Ascensia Diabetes Care</organization>
      <phone>574-257-3040</phone>
      <email>carmine.greene@ascensia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

